The Editor's Roundtable: arterial thrombosis and acute coronary syndromes.

[1]  K. Furie,et al.  Heart disease and stroke statistics--2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. , 2007, Circulation.

[2]  Adelaide,et al.  Bivalirudin for patients with acute coronary syndromes. , 2006, The New England journal of medicine.

[3]  C. Meuleman.  Comparaison of fondaparinux and enoxaparin in acute coronary syndromes. The Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators. , 2006 .

[4]  W. Gibler,et al.  Low-molecular-weight heparin compared with unfractionated heparin for patients with non–ST-segment elevation acute coronary syndromes treated with glycoprotein IIb/IIIa inhibitors: Results from the CRUSADE initiative , 2006, Journal of Thrombosis and Thrombolysis.

[5]  Salim Yusuf,et al.  Comparison of fondaparinux and enoxaparin in acute coronary syndromes. , 2006, The New England journal of medicine.

[6]  E. Antman,et al.  Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. , 2006, The New England journal of medicine.

[7]  S. Yusuf,et al.  Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. , 2006, JAMA.

[8]  G. Raskob,et al.  Fondaparinux or Enoxaparin for the Initial Treatment of Symptomatic Deep Venous Thrombosis , 2004, Annals of Internal Medicine.

[9]  M Gent,et al.  Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. , 2003, The New England journal of medicine.

[10]  B. Eriksson,et al.  Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. , 2002, Archives of internal medicine.

[11]  M. Hadamitzky,et al.  Major benefit from antiplatelet therapy for patients at high risk for adverse cardiac events after coronary Palmaz-Schatz stent placement: analysis of a prospective risk stratification protocol in the Intracoronary Stenting and Antithrombotic Regimen (ISAR) trial. , 1997, Circulation.

[12]  K. Wiklund,et al.  Low-molecular-weight heparin during instability in coronary artery disease , 1996 .

[13]  V. Fuster,et al.  The pathogenesis of coronary artery disease and the acute coronary syndromes (2). , 1992, The New England journal of medicine.

[14]  M. Davies,et al.  Community study of the causes of "natural" sudden death. , 1988, BMJ.

[15]  M S Golden,et al.  Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. , 1980, The New England journal of medicine.

[16]  Kenneth W. Duckett,et al.  PLASMA-FIBRINOGEN AND THROMBOEMBOLI AFTER MYOCARDIAL INFARCTION , 1976, The Lancet.

[17]  M. Davies,et al.  Pathology of acute myocardial infarction with particular reference to occlusive coronary thrombi. , 1976, British heart journal.